During the last session, Unicycive Therapeutics Inc (NASDAQ:UNCY)’s traded shares were 1.62 million, with the beta value of the company hitting 2.35. At the end of the trading day, the stock’s price was $0.54, reflecting an intraday gain of 4.90% or $0.03. The 52-week high for the UNCY share is $1.82, that puts it down -237.04 from that peak though still a striking 62.96% gain since the share price plummeted to a 52-week low of $0.20. The company’s market capitalization is $50.48M, and the average intraday trading volume over the past 10 days was 1.59 million shares, and the average trade volume was 2.25 million shares over the past three months.
Unicycive Therapeutics Inc (UNCY) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. UNCY has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.15.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Unicycive Therapeutics Inc (NASDAQ:UNCY) trade information
Unicycive Therapeutics Inc (UNCY) registered a 4.90% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.90% in intraday trading to $0.54, hitting a weekly high. The stock’s 5-day price performance is 28.08%, and it has moved by 40.35% in 30 days. Based on these gigs, the overall price performance for the year is -6.19%. The short interest in Unicycive Therapeutics Inc (NASDAQ:UNCY) is 1.05 million shares and it means that shorts have 0.68 day(s) to cover.
Unicycive Therapeutics Inc (UNCY) estimates and forecasts
Statistics show that Unicycive Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Unicycive Therapeutics Inc (UNCY) shares have gone down -52.23% during the last six months, with a year-to-date growth rate less than the industry average at 0.00% against 17.60. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -15.40% this quarter and then jump 40.90% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -77.09%. While earnings are projected to return 42.97% in 2024.
UNCY Dividends
Unicycive Therapeutics Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Unicycive Therapeutics Inc (NASDAQ:UNCY)’s Major holders
Unicycive Therapeutics Inc insiders own 6.73% of total outstanding shares while institutional holders control 38.26%, with the float percentage being 41.02%. VIVO CAPITAL, LLC is the largest shareholder of the company, while 29.0 institutions own stock in it. As of 2024-06-30, the company held over 3.47 million shares (or 9.9395% of all shares), a total value of $1.74 million in shares.
The next largest institutional holding, with 3.47 million shares, is of LOGOS GLOBAL MANAGEMENT LP’s that is approximately 9.9389% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.74 million.
